BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60:578-583. [PMID: 19180481 DOI: 10.1002/art.24249] [Cited by in Crossref: 186] [Cited by in F6Publishing: 154] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Hesselstrand R, Distler JHW, Riemekasten G, Wuttge DM, Törngren M, Nyhlén HC, Andersson F, Eriksson H, Sparre B, Tuvesson H, Distler O. An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod. Arthritis Res Ther 2021;23:204. [PMID: 34330322 DOI: 10.1186/s13075-021-02573-0] [Reference Citation Analysis]
2 Horimoto AM, da Costa IP. Overlap between systemic sclerosis and rheumatoid arthritis: a distinct clinical entity? Rev Bras Reumatol Engl Ed 2016;56:287-98. [PMID: 27476621 DOI: 10.1016/j.rbre.2014.12.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Debes GF, McGettigan SE. Skin-Associated B Cells in Health and Inflammation. J Immunol 2019;202:1659-66. [PMID: 30833422 DOI: 10.4049/jimmunol.1801211] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 21.0] [Reference Citation Analysis]
4 Distler JHW, Györfi A, Ramanujam M, Whitfield ML, Königshoff M, Lafyatis R. Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol 2019;15:705-30. [DOI: 10.1038/s41584-019-0322-7] [Cited by in Crossref: 103] [Cited by in F6Publishing: 99] [Article Influence: 51.5] [Reference Citation Analysis]
5 Baron M. Targeted Therapy in Systemic Sclerosis. Rambam Maimonides Med J 2016;7. [PMID: 27824545 DOI: 10.5041/RMMJ.10257] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
6 Pendergrass SA, Lemaire R, Francis IP, Mahoney JM, Lafyatis R, Whitfield ML. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 2012;132:1363-73. [PMID: 22318389 DOI: 10.1038/jid.2011.472] [Cited by in Crossref: 98] [Cited by in F6Publishing: 93] [Article Influence: 10.9] [Reference Citation Analysis]
7 Hasegawa M. B lymphocytes: Shedding new light on the pathogenesis of systemic sclerosis. The Journal of Dermatology 2010;37:3-10. [DOI: 10.1111/j.1346-8138.2009.00763.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
8 Smith V, Piette Y, van Praet JT, Decuman S, Deschepper E, Elewaut D, De Keyser F. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40:52-57. [PMID: 23118116 DOI: 10.3899/jrheum.120778] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 7.2] [Reference Citation Analysis]
9 Yoshizaki A. B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets. J Dermatol 2016;43:39-45. [PMID: 26782005 DOI: 10.1111/1346-8138.13184] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
10 Avouac J, Clements PJ, Khanna D, Furst DE, Allanore Y. Articular involvement in systemic sclerosis. Rheumatology 2012;51:1347-56. [DOI: 10.1093/rheumatology/kes041] [Cited by in Crossref: 52] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
11 Rath E, Zwerina J, Oppl B, Nell-duxneuner V. Efficacy and safety of rituximab in rheumatic diseases. Wien Med Wochenschr 2015;165:28-35. [DOI: 10.1007/s10354-014-0331-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
12 Giuggioli D, Lumetti F, Colaci M, Fallahi P, Antonelli A, Ferri C. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmunity Reviews 2015;14:1072-8. [DOI: 10.1016/j.autrev.2015.07.008] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 15.0] [Reference Citation Analysis]
13 Haroon M, McLaughlin P, Henry M, Harney S. Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids. Ther Adv Respir Dis 2011;5:299-304. [PMID: 21593063 DOI: 10.1177/1753465811407786] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
14 Johnson ME, Pioli PA, Whitfield ML. Gene expression profiling offers insights into the role of innate immune signaling in SSc. Semin Immunopathol 2015;37:501-9. [PMID: 26223504 DOI: 10.1007/s00281-015-0512-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
15 De Ravin SS, Cowen EW, Zarember KA, Whiting-Theobald NL, Kuhns DB, Sandler NG, Douek DC, Pittaluga S, Poliani PL, Lee YN, Notarangelo LD, Wang L, Alt FW, Kang EM, Milner JD, Niemela JE, Fontana-Penn M, Sinal SH, Malech HL. Hypomorphic Rag mutations can cause destructive midline granulomatous disease. Blood 2010;116:1263-71. [PMID: 20489056 DOI: 10.1182/blood-2010-02-267583] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 7.5] [Reference Citation Analysis]
16 Dieudé P, Wipff J, Guedj M, Ruiz B, Melchers I, Hachulla E, Riemekasten G, Diot E, Hunzelmann N, Sibilia J, Tiev K, Mouthon L, Cracowski JL, Carpentier PH, Distler J, Amoura Z, Tarner I, Avouac J, Meyer O, Kahan A, Boileau C, Allanore Y. BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4: Association of BANK1 with SSc. Arthritis & Rheumatism 2009;60:3447-54. [DOI: 10.1002/art.24885] [Cited by in Crossref: 84] [Cited by in F6Publishing: 73] [Article Influence: 7.0] [Reference Citation Analysis]
17 Stasi C, Triboli E, Arena U, Urraro T, Petrarca A, Gragnani L, Laffi G, Zignego AL. Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. J Transl Med. 2014;12:21. [PMID: 24456582 DOI: 10.1186/1479-5876-12-21] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
18 Sanges S, Guerrier T, Launay D, Lefèvre G, Labalette M, Forestier A, Sobanski V, Corli J, Hauspie C, Jendoubi M, Yakoub-Agha I, Hatron PY, Hachulla E, Dubucquoi S. Role of B cells in the pathogenesis of systemic sclerosis. Rev Med Interne 2017;38:113-24. [PMID: 27020403 DOI: 10.1016/j.revmed.2016.02.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
19 Daoussis D, Liossis SN, Yiannopoulos G, Andonopoulos AP. B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol. 2011;2011:214013. [PMID: 21826145 DOI: 10.1155/2011/214013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
20 Haustein U. Systemic Sclerosis - An Update. Lab Med 2011;42:562-72. [DOI: 10.1309/lm9ob5bz4osnvgvf] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
21 Garrana SH, Buckley JR, Rosado-de-Christenson ML, Martínez-Jiménez S, Muñoz P, Borsa JJ. Multimodality Imaging of Focal and Diffuse Fibrosing Mediastinitis. Radiographics 2019;39:651-67. [PMID: 30951437 DOI: 10.1148/rg.2019180143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
22 Mathes AL, Christmann RB, Stifano G, Affandi AJ, Radstake TR, Farina GA, Padilla C, McLaughlin S, Lafyatis R. Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin. Ann Rheum Dis 2014;73:1864-72. [PMID: 23873879 DOI: 10.1136/annrheumdis-2012-202814] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
23 Moazedi-Fuerst FC, Kielhauser SM, Brickmann K, Hermann J, Lutfi A, Meilinger M, Brezinschek HP, Graninger WB. Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen. Scand J Rheumatol 2014;43:257-8. [PMID: 24611681 DOI: 10.3109/03009742.2013.869617] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
24 Daoussis D, Antonopoulos I, Liossis SN, Yiannopoulos G, Andonopoulos AP. Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum 2012;41:822-9. [PMID: 22221908 DOI: 10.1016/j.semarthrit.2011.11.007] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
25 Yoo W. Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int 2012;32:795-8. [DOI: 10.1007/s00296-009-1347-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
26 Sanges S, Jendoubi M, Kavian N, Hauspie C, Speca S, Crave JC, Guerrier T, Lefèvre G, Sobanski V, Savina A, Hachulla E, Hatron PY, Labalette M, Batteux F, Dubucquoi S, Launay D. B Cell Homeostasis and Functional Properties Are Altered in an Hypochlorous Acid-Induced Murine Model of Systemic Sclerosis. Front Immunol 2017;8:53. [PMID: 28223983 DOI: 10.3389/fimmu.2017.00053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Matsushita T, Takehara K. An update on biomarker discovery and use in systemic sclerosis. Expert Review of Molecular Diagnostics 2017;17:823-33. [DOI: 10.1080/14737159.2017.1356722] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
28 Boin F, Wigley FM. Clinical Features and Treatment of Scleroderma. Kelley's Textbook of Rheumatology. Elsevier; 2013. pp. 1366-1403.e4. [DOI: 10.1016/b978-1-4377-1738-9.00084-0] [Cited by in Crossref: 7] [Article Influence: 0.9] [Reference Citation Analysis]
29 Takahashi T, Asano Y, Sugawara K, Yamashita T, Nakamura K, Saigusa R, Ichimura Y, Toyama T, Taniguchi T, Akamata K, Noda S, Yoshizaki A, Tsuruta D, Trojanowska M, Sato S. Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma. J Exp Med 2017;214:1129-51. [PMID: 28232470 DOI: 10.1084/jem.20160247] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 12.0] [Reference Citation Analysis]
30 Assassi S, Mayes MD. What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis? Curr Opin Rheumatol 2013;25:686-91. [PMID: 24061076 DOI: 10.1097/01.bor.0000434672.77891.41] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
31 Hasegawa M, Takehara K. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines. Semin Arthritis Rheum 2012;42:281-96. [PMID: 22542279 DOI: 10.1016/j.semarthrit.2012.03.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
32 Odaka M, Hasegawa M, Hamaguchi Y, Ishiura N, Kumada S, Matsushita T, Komura K, Sato S, Takehara K, Fujimoto M. Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis. Clin Exp Immunol 2010;159:176-84. [PMID: 19919568 DOI: 10.1111/j.1365-2249.2009.04059.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
33 Wu M, Mohan C. B-cells in systemic sclerosis: emerging evidence from genetics to phenotypes. Curr Opin Rheumatol 2015;27:537-41. [PMID: 26285102 DOI: 10.1097/BOR.0000000000000215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
34 Saul L, Ilieva KM, Bax HJ, Karagiannis P, Correa I, Rodriguez-Hernandez I, Josephs DH, Tosi I, Egbuniwe IU, Lombardi S, Crescioli S, Hobbs C, Villanova F, Cheung A, Geh JL, Healy C, Harries M, Sanz-Moreno V, Fear DJ, Spicer JF, Lacy KE, Nestle FO, Karagiannis SN. IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin. Sci Rep 2016;6:29736. [PMID: 27411958 DOI: 10.1038/srep29736] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
35 Goswami RP, Ray A, Chatterjee M, Mukherjee A, Sircar G, Ghosh P. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Rheumatology (Oxford) 2021;60:557-67. [PMID: 33164098 DOI: 10.1093/rheumatology/keaa550] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
36 Chartrand S, Fischer A. Management of connective tissue disease-associated interstitial lung disease. Rheum Dis Clin North Am 2015;41:279-94. [PMID: 25836643 DOI: 10.1016/j.rdc.2015.01.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
37 Quaresma JAS. Organization of the Skin Immune System and Compartmentalized Immune Responses in Infectious Diseases. Clin Microbiol Rev 2019;32:e00034-18. [PMID: 31366611 DOI: 10.1128/CMR.00034-18] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
38 de Paula DR, Klem FB, Lorencetti PG, Muller C, Azevedo VF. Rituximab-induced regression of CREST-related calcinosis. Clin Rheumatol 2013;32:281-3. [DOI: 10.1007/s10067-012-2124-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
39 Zulian F, Balzarin M, Birolo C. Recent advances in the management of juvenile systemic sclerosis. Expert Review of Clinical Immunology 2017;13:361-9. [DOI: 10.1080/1744666x.2017.1243467] [Cited by in Crossref: 8] [Article Influence: 1.6] [Reference Citation Analysis]
40 Beyer C, Distler O, Distler JH. Innovative antifibrotic therapies in systemic sclerosis. Curr Opin Rheumatol 2012;24:274-80. [PMID: 22450392 DOI: 10.1097/BOR.0b013e3283524b9a] [Cited by in Crossref: 43] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
41 Taher TE, Ong VH, Bystrom J, Hillion S, Simon Q, Denton CP, Pers JO, Abraham DJ, Mageed RA. Association of Defective Regulation of Autoreactive Interleukin-6-Producing Transitional B Lymphocytes With Disease in Patients With Systemic Sclerosis. Arthritis Rheumatol 2018;70:450-61. [PMID: 29193892 DOI: 10.1002/art.40390] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
42 Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol 2010;6:578-87. [PMID: 20703220 DOI: 10.1038/nrrheum.2010.104] [Cited by in Crossref: 152] [Cited by in F6Publishing: 117] [Article Influence: 13.8] [Reference Citation Analysis]
43 Tai Y, Woods EL, Dally J, Kong D, Steadman R, Moseley R, Midgley AC. Myofibroblasts: Function, Formation, and Scope of Molecular Therapies for Skin Fibrosis. Biomolecules 2021;11:1095. [PMID: 34439762 DOI: 10.3390/biom11081095] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
44 Simms RW, Lafyatis R. Rituximab: a potential therapeutic advance in scleroderma: what is the evidence? Rheumatology (Oxford) 2010;49:201-2. [PMID: 20032221 DOI: 10.1093/rheumatology/kep421] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
45 Daoussis D, Andonopoulos AP. Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: comment on the article by Yoo. Rheumatol Int 2011;31:841-2. [PMID: 20376665 DOI: 10.1007/s00296-010-1485-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
46 Taroni JN, Mahoney JM, Whitfield ML. The mechanistic implications of gene expression studies in SSc: Insights from Systems Biology. Curr Treatm Opt Rheumatol 2017;3:181-92. [PMID: 29520335 DOI: 10.1007/s40674-017-0072-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
47 Atienza-Mateo B, Remuzgo-Martínez S, Prieto-Peña D, Mora Cuesta VM, Iturbe-Fernández D, Llorca J, Sánchez-Bilbao L, Corrales A, Blanco Rodríguez G, Gómez-Román JJ, Cifrián JM, González-Gay MÁ. Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review. J Clin Med 2020;9:E3070. [PMID: 32977717 DOI: 10.3390/jcm9103070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
48 Boonstra M, Meijs J, Dorjée AL, Marsan NA, Schouffoer A, Ninaber MK, Quint KD, Bonte-Mineur F, Huizinga TWJ, Scherer HU, de Vries-Bouwstra JK. Rituximab in early systemic sclerosis. RMD Open 2017;3:e000384. [PMID: 28879049 DOI: 10.1136/rmdopen-2016-000384] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
49 Eckes B, Moinzadeh P, Sengle G, Hunzelmann N, Krieg T. Molecular and cellular basis of scleroderma. J Mol Med 2014;92:913-24. [DOI: 10.1007/s00109-014-1190-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
50 Asano Y. Future treatments in systemic sclerosis. The Journal of Dermatology 2010;37:54-70. [DOI: 10.1111/j.1346-8138.2009.00758.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 7.7] [Reference Citation Analysis]
51 Hinchcliff M, Huang CC, Wood TA, Matthew Mahoney J, Martyanov V, Bhattacharyya S, Tamaki Z, Lee J, Carns M, Podlusky S, Sirajuddin A, Shah SJ, Chang RW, Lafyatis R, Varga J, Whitfield ML. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol 2013;133:1979-89. [PMID: 23677167 DOI: 10.1038/jid.2013.130] [Cited by in Crossref: 97] [Cited by in F6Publishing: 85] [Article Influence: 12.1] [Reference Citation Analysis]
52 Tang R, Yu J, Shi Y, Zou P, Zeng Z, Tang B, Wang Y, Ling G, Luo M, Xiao R. Safety and efficacy of Rituximab in systemic sclerosis: A systematic review and meta-analysis. Int Immunopharmacol 2020;83:106389. [PMID: 32172205 DOI: 10.1016/j.intimp.2020.106389] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
53 Moazedi-Fuerst FC, Kielhauser SM, Bodo K, Graninger WB. Dosage of rituximab in systemic sclerosis: 2-year results of five cases. Clin Exp Dermatol 2015;40:211-2. [PMID: 25250643 DOI: 10.1111/ced.12450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
54 Narváez J, LLuch J, Molina-Molina M, Vicens-Zygmunt V, Luburich P, Yañez MA, Nolla JM. Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression. Semin Arthritis Rheum 2020;50:977-87. [PMID: 32911289 DOI: 10.1016/j.semarthrit.2020.08.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
55 Mavropoulos A, Simopoulou T, Varna A, Liaskos C, Katsiari CG, Bogdanos DP, Sakkas LI. Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis: BREG CELLS IN SYSTEMIC SCLEROSIS. Arthritis & Rheumatology 2016;68:494-504. [DOI: 10.1002/art.39437] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 14.8] [Reference Citation Analysis]
56 Nguyen AV, Soulika AM. The Dynamics of the Skin's Immune System. Int J Mol Sci 2019;20:E1811. [PMID: 31013709 DOI: 10.3390/ijms20081811] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 32.0] [Reference Citation Analysis]
57 Cappelli S, Bellando-Randone S, Guiducci S, Matucci-Cerinic M. Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis? Rheumatology (Oxford) 2014;53:975-87. [PMID: 24185765 DOI: 10.1093/rheumatology/ket312] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
58 Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology 2018;57:2106-13. [DOI: 10.1093/rheumatology/key213] [Cited by in Crossref: 83] [Cited by in F6Publishing: 62] [Article Influence: 27.7] [Reference Citation Analysis]
59 Khatri S, Torok KS, Mirizio E, Liu C, Astakhova K. Autoantibodies in Morphea: An Update. Front Immunol 2019;10:1487. [PMID: 31354701 DOI: 10.3389/fimmu.2019.01487] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
60 Bruni C, Praino E, Allanore Y, Distler O, Gabrielli A, Iannone F, Matucci-Cerinic M. Use of biologics and other novel therapies for the treatment of systemic sclerosis. Expert Rev Clin Immunol 2017;13:469-82. [PMID: 27899043 DOI: 10.1080/1744666X.2017.1263153] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 4.6] [Reference Citation Analysis]
61 Vilela VS, Maretti GB, Gama LMDS, Costa CHD, Rufino RL, Levy RA. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center. Revista Brasileira de Reumatologia (English Edition) 2016;56:458-63. [DOI: 10.1016/j.rbre.2016.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
62 Daoussis D, Tsamandas AC, Liossis SN, Antonopoulos I, Karatza E, Yiannopoulos G, Andonopoulos AP. B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis Res Ther. 2012;14:R145. [PMID: 22697462 DOI: 10.1186/ar3879] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
63 Egbuniwe IU, Karagiannis SN, Nestle FO, Lacy KE. Revisiting the role of B cells in skin immune surveillance. Trends Immunol. 2015;36:102-111. [PMID: 25616715 DOI: 10.1016/j.it.2014.12.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 7.8] [Reference Citation Analysis]
64 Asano Y. Recent advances in the treatment of skin involvement in systemic sclerosis. Inflamm Regen 2017;37:12. [PMID: 29259711 DOI: 10.1186/s41232-017-0047-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Melissaropoulos K, Daoussis D. B cells in systemic sclerosis: from pathophysiology to treatment. Clin Rheumatol 2021;40:2621-31. [PMID: 33745085 DOI: 10.1007/s10067-021-05665-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Jee AS, Corte TJ. Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). Drugs 2019;79:1511-28. [PMID: 31399860 DOI: 10.1007/s40265-019-01178-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
67 Ah Kioon MD, Tripodo C, Fernandez D, Kirou KA, Spiera RF, Crow MK, Gordon JK, Barrat FJ. Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Sci Transl Med 2018;10:eaam8458. [PMID: 29321259 DOI: 10.1126/scitranslmed.aam8458] [Cited by in Crossref: 90] [Cited by in F6Publishing: 79] [Article Influence: 45.0] [Reference Citation Analysis]
68 Zamanian RT, Badesch D, Chung L, Domsic RT, Medsger T, Pinckney A, Keyes-Elstein L, D'Aveta C, Spychala M, White RJ, Hassoun PM, Torres F, Sweatt AJ, Molitor JA, Khanna D, Maecker H, Welch B, Goldmuntz E, Nicolls MR. Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. Am J Respir Crit Care Med 2021;204:209-21. [PMID: 33651671 DOI: 10.1164/rccm.202009-3481OC] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
69 Clarke JT, Werth VP. Rheumatic manifestations of skin disease. Curr Opin Rheumatol 2010;22:78-84. [PMID: 19851110 DOI: 10.1097/BOR.0b013e328333b9e2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
70 Sakkas LI, Bogdanos DP. Systemic sclerosis: New evidence re-enforces the role of B cells. Autoimmun Rev 2016;15:155-61. [PMID: 26497107 DOI: 10.1016/j.autrev.2015.10.005] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
71 Vilela VS, Maretti GB, Silva Gama LMD, Costa CHD, Rufino RL, Levy RA. Tratamento da esclerose sistêmica com rituximabe: uma série de 10 casos em centro único. Revista Brasileira de Reumatologia 2016;56:458-63. [DOI: 10.1016/j.rbr.2016.04.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
72 Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol. 2010;29:1167-1168. [PMID: 20532938 DOI: 10.1007/s10067-010-1498-z] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
73 Moradzadeh M, Aghaei M, Mehrbakhsh Z, Arab-Bafrani Z, Abdollahi N. Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis. Clin Rheumatol 2021. [PMID: 33796953 DOI: 10.1007/s10067-021-05698-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Quillinan NP, Denton CP. Disease-modifying treatment in systemic sclerosis: current status. Curr Opin Rheumatol 2009;21:636-41. [PMID: 19726995 DOI: 10.1097/BOR.0b013e3283310d57] [Cited by in Crossref: 33] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
75 Abdallah F, Mijouin L, Pichon C. Skin Immune Landscape: Inside and Outside the Organism. Mediators Inflamm. 2017;2017:5095293. [PMID: 29180836 DOI: 10.1155/2017/5095293] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
76 Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74:1188-1194. [PMID: 24442885 DOI: 10.1136/annrheumdis-2013-204522] [Cited by in Crossref: 226] [Cited by in F6Publishing: 195] [Article Influence: 32.3] [Reference Citation Analysis]
77 Zhu JL, Black SM, Chen HW, Jacobe HT. Emerging treatments for scleroderma/systemic sclerosis. Fac Rev 2021;10:43. [PMID: 34131653 DOI: 10.12703/r/10-43] [Reference Citation Analysis]
78 Topal AA, Dhurat RS. Scleroderma therapy: clinical overview of current trends and future perspective. Rheumatol Int 2013;33:1-18. [PMID: 23011088 DOI: 10.1007/s00296-012-2486-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
79 Daoussis D, Tsamandas A, Antonopoulos I, Filippopoulou A, Papachristou DJ, Papachristou NI, Andonopoulos AP, Liossis SN. B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis. Arthritis Res Ther 2016;18:118. [PMID: 27208972 DOI: 10.1186/s13075-016-1017-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
80 Engel P, Gómez-Puerta JA, Ramos-Casals M, Lozano F, Bosch X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011;63:127-56. [PMID: 21245206 DOI: 10.1124/pr.109.002006] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 7.2] [Reference Citation Analysis]
81 Asano Y, Varga J. Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies. Semin Cell Dev Biol 2020;101:146-60. [PMID: 31859147 DOI: 10.1016/j.semcdb.2019.12.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
82 Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, Yao W, Li J, Streicher K, McKeever K, White B, Katz E, Drappa J, Sweeny S, Herbst R. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther 2016;18:131. [PMID: 27267753 DOI: 10.1186/s13075-016-1021-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
83 Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett 2018;195:76-82. [PMID: 29307688 DOI: 10.1016/j.imlet.2018.01.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
84 Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med 2011;17:362-7. [PMID: 21597375 DOI: 10.1097/MCP.0b013e3283483ea5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 12] [Article Influence: 4.1] [Reference Citation Analysis]
85 Kobayashi A, Okamoto H. Treatment of interstitial lung diseases associated with connective tissue diseases. Expert Rev Clin Pharmacol 2012;5:219-27. [PMID: 22390563 DOI: 10.1586/ecp.12.9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
86 Vicente-Rabaneda EF, Serra López-Matencio JM, Ancochea J, Blanco R, González-Gay MÁ, Castañeda S. Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. Expert Opin Drug Saf 2021;:1-23. [PMID: 34433372 DOI: 10.1080/14740338.2021.1973428] [Reference Citation Analysis]
87 De Luca G, Tomelleri A, Dagna L, Matucci-Cerinic M. The target on B cells in Systemic Sclerosis: a "midsummer dream" to extinguish inflammation and prevent early disease progression to fibrosis. Clin Rheumatol 2021;40:2529-33. [PMID: 34021841 DOI: 10.1007/s10067-021-05733-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Lafyatis R. Application of biomarkers to clinical trials in systemic sclerosis. Curr Rheumatol Rep 2012;14:47-55. [PMID: 22052444 DOI: 10.1007/s11926-011-0216-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
89 Higashioka K, Kikushige Y, Ayano M, Kimoto Y, Mitoma H, Kikukawa M, Akahoshi M, Arinobu Y, Horiuchi T, Akashi K, Niiro H. Generation of a novel CD30+ B cell subset producing GM-CSF and its possible link to the pathogenesis of systemic sclerosis. Clin Exp Immunol 2020;201:233-43. [PMID: 32538493 DOI: 10.1111/cei.13477] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
90 Bosello S, Angelucci C, Lama G, Alivernini S, Proietti G, Tolusso B, Sica G, Gremese E, Ferraccioli G. Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression. Arthritis Res Ther 2018;20:75. [PMID: 29669578 DOI: 10.1186/s13075-018-1569-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
91 Misra DP, Ahmed S, Agarwal V. Is biological therapy in systemic sclerosis the answer? Rheumatol Int 2020;40:679-94. [PMID: 31960079 DOI: 10.1007/s00296-020-04515-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
92 Bellan M, Patrucco F, Barone-adesi F, Gavelli F, Castello LM, Nerviani A, Andreoli L, Cavagna L, Pirisi M, Sainaghi PP. Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review. Autoimmunity Reviews 2020;19:102453. [DOI: 10.1016/j.autrev.2019.102453] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
93 Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther 2017;11:2891-904. [PMID: 29042750 DOI: 10.2147/DDDT.S139248] [Cited by in Crossref: 46] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
94 Daoussis D, Andonopoulos AP. B cell depletion in scleroderma lung disease: A promising new treatment? World J Rheumatol 2013; 3(2): 9-11 [DOI: 10.5499/wjr.v3.i2.9] [Reference Citation Analysis]
95 Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49:271-280. [PMID: 19447770 DOI: 10.1093/rheumatology/kep093] [Cited by in Crossref: 246] [Cited by in F6Publishing: 208] [Article Influence: 20.5] [Reference Citation Analysis]
96 Leask A. B cell block: is rituximab a new possible treatment for systemic sclerosis? J Cell Commun Signal 2010;4:201-2. [PMID: 21234128 DOI: 10.1007/s12079-010-0107-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
97 Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? Int J Infect Dis. 2011;15:e2-16. [PMID: 21074471 DOI: 10.1016/j.ijid.2010.03.025] [Cited by in Crossref: 131] [Cited by in F6Publishing: 108] [Article Influence: 11.9] [Reference Citation Analysis]
98 Bassyouni IH, Azab NA, El-dakrony EM, Fawzi MM, Ghanoum R, Bassyouni RH. Elevated serum levels of a proliferation-inducing ligand in patients with systemic sclerosis: Possible association with myositis? Joint Bone Spine 2011;78:56-61. [DOI: 10.1016/j.jbspin.2010.05.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
99 Zigrino P, Sengle G. Fibrillin microfibrils and proteases, key integrators of fibrotic pathways. Advanced Drug Delivery Reviews 2019;146:3-16. [DOI: 10.1016/j.addr.2018.04.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
100 Daoussis D, Liossis SN. B cells tell scleroderma fibroblasts to produce collagen. Arthritis Res Ther 2013;15:125. [PMID: 24611177 DOI: 10.1186/ar4392] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
101 Hogan V, Wheater G, Huigens C, Hgle T, van Laar JM. Role of B Cells in Rheumatic Autoimmune Disease. Open Arth J 2010;3:32-6. [DOI: 10.2174/1876539401003010032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
102 Mendoza FA, Mansoor M, Jimenez SA. Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives. Expert Opin Orphan Drugs 2016;4:31-47. [PMID: 27812432 DOI: 10.1517/21678707.2016.1114454] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
103 Ramos-casals M, Fonollosa-pla V, Brito-zerón P, Sisó-almirall A. Targeted therapy for systemic sclerosis: how close are we? Nat Rev Rheumatol 2010;6:269-78. [DOI: 10.1038/nrrheum.2010.48] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
104 van Laar JM. B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis. Arthritis Res Ther 2010;12:112. [PMID: 20441607 DOI: 10.1186/ar2977] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
105 van Laar JM, Simms RW. Immunomodulatory, Immunoablative, and Biologic Therapies. In: Varga J, Denton CP, Wigley FM, Allanore Y, Kuwana M, editors. Scleroderma. Cham: Springer International Publishing; 2017. pp. 567-82. [DOI: 10.1007/978-3-319-31407-5_41] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
106 Rubbert-Roth A. [Anti-B-cell strategies in vasculitides and collagenoses]. Z Rheumatol 2009;68:390-6. [PMID: 19551392 DOI: 10.1007/s00393-009-0439-1] [Reference Citation Analysis]
107 Xing NS, Fan GZ, Yan F, Liu YP, Zhang R. Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis. Int Immunopharmacol 2021;95:107524. [PMID: 33721757 DOI: 10.1016/j.intimp.2021.107524] [Reference Citation Analysis]
108 Katsiari CG, Simopoulou T, Alexiou I, Sakkas LI. Immunotherapy of systemic sclerosis. Hum Vaccin Immunother 2018;14:2559-67. [PMID: 29985736 DOI: 10.1080/21645515.2018.1491508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
109 Vacchi C, Manfredi A, Cassone G, Erre GL, Salvarani C, Sebastiani M. Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease. Drugs Context 2021;10:2020-8-7. [PMID: 33505478 DOI: 10.7573/dic.2020-8-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Berghen N, Vulsteke JB, Westhovens R, Lenaerts J, De Langhe E. Rituximab in systemic autoimmune rheumatic diseases: indications and practical use. Acta Clin Belg 2019;74:272-9. [PMID: 30253707 DOI: 10.1080/17843286.2018.1521904] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
111 Hunzelmann N, Krieg T. Scleroderma: from pathophysiology to novel therapeutic approaches. Exp Dermatol 2010;19:393-400. [PMID: 20507361 DOI: 10.1111/j.1600-0625.2010.01082.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
112 Asano Y, Jinnin M, Kawaguchi Y, Kuwana M, Goto D, Sato S, Takehara K, Hatano M, Fujimoto M, Mugii N, Ihn H. Diagnostic criteria, severity classification and guidelines of systemic sclerosis. J Dermatol 2018;45:633-91. [PMID: 29687465 DOI: 10.1111/1346-8138.14162] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
113 Erre GL, Sebastiani M, Fenu MA, Zinellu A, Floris A, Cavagna L, Renzoni E, Manfredi A, Passiu G, Woodman RJ, Mangoni AA. Efficacy, Safety, and Tolerability of Treatments for Systemic Sclerosis-Related Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis. J Clin Med 2020;9:E2560. [PMID: 32784580 DOI: 10.3390/jcm9082560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
114 Del Papa N, Zaccara E. From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis. Best Pract Res Clin Rheumatol 2015;29:756-69. [PMID: 27107511 DOI: 10.1016/j.berh.2016.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
115 Becker M, Müller-ladner U, Riemekasten G. Implementation von Leitlinien für eine Therapie der systemischen Sklerose (Sklerodermie): Wunsch und Wirklichkeit. Z Rheumatol 2010;69:310-7. [DOI: 10.1007/s00393-009-0523-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
116 Postlethwaite AE, Harris LJ, Raza SH, Kodura S, Akhigbe T. Pharmacotherapy of systemic sclerosis. Expert Opin Pharmacother 2010;11:789-806. [PMID: 20210685 DOI: 10.1517/14656561003592177] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
117 Blank RB, Nwawka OK, Yusov AA, Gordon JK. Inflammatory arthritis in systemic sclerosis: What to do? Journal of Scleroderma and Related Disorders 2019;4:3-16. [DOI: 10.1177/2397198318779532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
118 Phumethum V, Jamal S, Johnson SR. Biologic therapy for systemic sclerosis: a systematic review. J Rheumatol 2011;38:289-96. [PMID: 21041277 DOI: 10.3899/jrheum.100361] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
119 Becker MO. [Systemic sclerosis : What is currently available for treatment?]. Internist (Berl) 2016;57:1155-63. [PMID: 27796473 DOI: 10.1007/s00108-016-0148-1] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
120 Wu M, Assassi S. The role of type 1 interferon in systemic sclerosis. Front Immunol 2013;4:266. [PMID: 24046769 DOI: 10.3389/fimmu.2013.00266] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
121 Melissaropoulos K, Liossis SN. Decreased CD22 expression and intracellular signaling aberrations in B cells of patients with systemic sclerosis. Rheumatol Int 2018;38:1225-34. [PMID: 29869007 DOI: 10.1007/s00296-018-4076-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
122 Whitfield ML. Editorial: Plasma and B Cell Gene Signatures: Quantitative Targeting and Monitoring of B Cell-Depleting Therapies in Autoimmune Diseases in the Genomic Era: Editorial. Arthritis & Rheumatology 2014;66:10-4. [DOI: 10.1002/art.38192] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
123 Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Korfiatis P, Yiannopoulos G, Andonopoulos AP. Is there a role for B-cell depletion as therapy for scleroderma A case report and review of the literature. Semin Arthritis Rheum. 2010;40:127-136. [PMID: 20004954 DOI: 10.1016/j.semarthrit.2009.09.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
124 Dall'Ara F, Lazzaroni MG, Antonioli CM, Airò P. Systemic sclerosis with anti-RNA polymerase III positivity following silicone breast implant rupture: possible role of B-cell depletion and implant removal in the treatment. Rheumatol Int 2017;37:847-51. [PMID: 28160072 DOI: 10.1007/s00296-017-3654-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
125 Sumida H, Asano Y, Tamaki Z, Aozasa N, Taniguchi T, Takahashi T, Toyama T, Ichimura Y, Noda S, Akamata K, Miyazaki M, Kuwano Y, Yanaba K, Sato S. Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. J Dermatol 2014;41:418-20. [PMID: 24801917 DOI: 10.1111/1346-8138.12461] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
126 Ong VH, Denton CP. Innovative therapies for systemic sclerosis. Current Opinion in Rheumatology 2010;22:264-72. [DOI: 10.1097/bor.0b013e328337c3d6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
127 Chung MP, Chung L. Drugs in phase I and phase II clinical trials for systemic sclerosis. Expert Opin Investig Drugs 2020;29:349-62. [PMID: 32178544 DOI: 10.1080/13543784.2020.1743973] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
128 Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, Georgiou P, Andonopoulos AP, Drosos AA, Sakkas L, Liossis SN. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 2017;46:625-31. [PMID: 27839742 DOI: 10.1016/j.semarthrit.2016.10.003] [Cited by in Crossref: 102] [Cited by in F6Publishing: 87] [Article Influence: 20.4] [Reference Citation Analysis]
129 Lerman I, Mitchell DC, Richardson CT. Human cutaneous B cells: what do we really know? Ann Transl Med 2021;9:440. [PMID: 33842661 DOI: 10.21037/atm-20-5185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Guillevin L. A contemporary update on scleroderma. Clin Rev Allergy Immunol 2011;40:75-7. [PMID: 20300968 DOI: 10.1007/s12016-010-8200-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
131 Showalter K, Gordon JK. Skin Histology in Systemic Sclerosis: a Relevant Clinical Biomarker. Curr Rheumatol Rep 2020;23:3. [PMID: 33244633 DOI: 10.1007/s11926-020-00970-z] [Reference Citation Analysis]
132 Ramos-casals M, Díaz-lagares C, Khamashta MA. Tratamiento depletivo de células B en enfermedades autoinmunitarias sistémicas. Recomendaciones de uso en la práctica clínica. Medicina Clínica 2011;136:257-63. [DOI: 10.1016/j.medcli.2010.03.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
133 Bosello S, De Santis M, Lama G, Spanò C, Angelucci C, Tolusso B, Sica G, Ferraccioli G. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010;12:R54. [PMID: 20338043 DOI: 10.1186/ar2965] [Cited by in Crossref: 122] [Cited by in F6Publishing: 101] [Article Influence: 11.1] [Reference Citation Analysis]
134 Eldoma M, Pope J. The contemporary management of systemic sclerosis. Expert Rev Clin Immunol 2018;14:573-82. [PMID: 29874475 DOI: 10.1080/1744666X.2018.1485490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
135 Viswanath V, Phiske MM, Gopalani VV. Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations. Indian J Dermatol 2013;58:255-68. [PMID: 23918994 DOI: 10.4103/0019-5154.113930] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
136 Terao C, Ohmura K, Kawaguchi Y, Nishimoto T, Kawasaki A, Takehara K, Furukawa H, Kochi Y, Ota Y, Ikari K, Sato S, Tohma S, Yamada R, Yamamoto K, Kubo M, Yamanaka H, Kuwana M, Tsuchiya N, Matsuda F, Mimori T. PLD4 as a novel susceptibility gene for systemic sclerosis in a Japanese population. Arthritis Rheum 2013;65:472-80. [PMID: 23124809 DOI: 10.1002/art.37777] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
137 Melissaropoulos K, Kraniotis P, Bogdanos D, Dimitroulas T, Sakkas L, Daoussis D. Targeting very early systemic sclerosis: a case-based review. Rheumatol Int 2019;39:1961-70. [PMID: 31254002 DOI: 10.1007/s00296-019-04357-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
138 Horimoto AMC, Costa IPD. Sobreposição de esclerose sistêmica e artrite reumatoide: uma entidade clínica distinta? Revista Brasileira de Reumatologia 2016;56:287-98. [DOI: 10.1016/j.rbr.2014.12.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
139 Leask A. Emerging targets for the treatment of scleroderma. Expert Opinion on Emerging Drugs 2012;17:173-9. [DOI: 10.1517/14728214.2012.678833] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
140 Connolly MK. Systemic sclerosis (scleroderma): remaining challenges. Ann Transl Med 2021;9:438. [PMID: 33842659 DOI: 10.21037/atm-20-5449] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Taroni JN, Martyanov V, Mahoney JM, Whitfield ML. A Functional Genomic Meta-Analysis of Clinical Trials in Systemic Sclerosis: Toward Precision Medicine and Combination Therapy. J Invest Dermatol 2017;137:1033-41. [PMID: 28011145 DOI: 10.1016/j.jid.2016.12.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
142 Borrirukwisitsak S, Tantayakom P, Katchamart W. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis. Clin Rheumatol 2021;40:2779-89. [PMID: 33428098 DOI: 10.1007/s10067-020-05542-1] [Reference Citation Analysis]
143 Thiebaut M, Launay D, Rivière S, Mahévas T, Bellakhal S, Hachulla E, Fain O, Mekinian A. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmunity Reviews 2018;17:582-7. [DOI: 10.1016/j.autrev.2017.12.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 17.0] [Reference Citation Analysis]
144 Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR network. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 2019;78:979-87. [PMID: 30967395 DOI: 10.1136/annrheumdis-2018-214816] [Cited by in Crossref: 69] [Cited by in F6Publishing: 58] [Article Influence: 34.5] [Reference Citation Analysis]
145 Gordon JK, Martyanov V, Franks JM, Bernstein EJ, Szymonifka J, Magro C, Wildman HF, Wood TA, Whitfield ML, Spiera RF. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial. Arthritis Rheumatol 2018;70:308-16. [PMID: 29073351 DOI: 10.1002/art.40358] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 11.5] [Reference Citation Analysis]
146 Peikert T, Colby TV, Midthun DE, Pairolero PC, Edell ES, Schroeder DR, Specks U. Fibrosing mediastinitis: clinical presentation, therapeutic outcomes, and adaptive immune response. Medicine (Baltimore) 2011;90:412-23. [PMID: 22033450 DOI: 10.1097/MD.0b013e318237c8e6] [Cited by in Crossref: 77] [Cited by in F6Publishing: 27] [Article Influence: 8.6] [Reference Citation Analysis]
147 Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, Pirronti T, Ferraccioli G. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum 2015;44:428-36. [PMID: 25300701 DOI: 10.1016/j.semarthrit.2014.09.002] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 13.1] [Reference Citation Analysis]
148 Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy. 2010;2:863-878. [PMID: 21091117 DOI: 10.2217/imt.10.69] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
149 Misra DP, Chowdhury AC, Phatak S, Agarwal V. Scleroderma: Not an orphan disease any more. World J Rheumatol 2015; 5(3): 131-141 [DOI: 10.5499/wjr.v5.i3.131] [Reference Citation Analysis]
150 Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G, Ferraccioli G. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 2011;10:624-30. [PMID: 21545850 DOI: 10.1016/j.autrev.2011.04.013] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
151 Zulian F. Scleroderma in children. Best Practice & Research Clinical Rheumatology 2017;31:576-95. [DOI: 10.1016/j.berh.2018.02.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
152 Rieder F, de Bruyn JR, Pham BT, Katsanos K, Annese V, Higgins PD, Magro F, Dotan I. Results of the 4th scientific workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease. J Crohns Colitis. 2014;8:1166-1178. [PMID: 24726695 DOI: 10.1016/j.crohns.2014.03.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
153 Ebata S, Yoshizaki A, Fukasawa T, Miura S, Takahashi T, Sumida H, Asano Y, Sato S. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. J Dermatol 2019;46:1006-13. [PMID: 31502326 DOI: 10.1111/1346-8138.15079] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
154 Mcqueen FM, Solanki K. Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today? Rheumatology 2015;54:757-67. [DOI: 10.1093/rheumatology/keu463] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]